Sildenafil Citrate for the Treatment of Established Pre-Eclampsia
Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Aug 30, 2005
Trial Information
Current as of August 28, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Subjects with pre-eclampsia defined as new hypertension with a diastolic BP of \> or = 90 mmHg on two occasions separated by at least 4 hrs arising after 20 weeks of pregnancy, associated with \>500 mg/24 hr proteinuria. Subjects with pre-existing hypertension (on treatment) need only fulfill proteinuria requirement.
- • Gestational age 24-34 w
- • Singleton pregnancy
- Exclusion Criteria:
- • Where urgent delivery is indicated
- • Where the fetus is suspected to have a structural or chromosomal abnormality
About Pfizer's Upjohn Has Merged With Mylan To Form Viatris Inc.
Viatris Inc. is a global healthcare company formed from the merger of Pfizer's Upjohn division and Mylan, dedicated to providing access to high-quality medicines, including generics and specialty pharmaceuticals. With a strong commitment to innovation and patient-centric solutions, Viatris leverages a diverse portfolio and extensive global reach to address the evolving healthcare needs of patients worldwide. The company aims to create sustainable healthcare solutions by combining expertise in pharmaceutical development, manufacturing, and distribution, ultimately enhancing patient outcomes and improving overall health systems.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dundee, , United Kingdom
London, , United Kingdom
Pembury, Kent, United Kingdom
Royal Tunbridge Wells, Kent, United Kingdom
Ashton Under Lyne, Lancs, United Kingdom
Bolton, , United Kingdom
Fife, , United Kingdom
Manchester, , United Kingdom
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials